Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Quanta Therapeutics Presents Data from KRAS Inhibitor
- Data highlight favorable preclinical profiles for two…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
KRAS
Immuneering Presents Preclinical Data with Lead Program
<!-- Name:DistributionId Value:8781719 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Revolution Medicines Announces Pricing of $300.0
<!-- Name:DistributionId Value:8780974 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream
<!-- Name:DistributionId Value:8746759 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
- Advertisement -
Revolution Medicines Announces Publication Describing
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric mTORC1-Selective Inhibitor and a…
Revolution Medicines to Regain Global Rights to RMC-4630
REDWOOD CITY, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Sanofi has provided…